2021
Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH
Goedeke L, Shulman GI. Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH. Molecular Metabolism 2021, 46: 101178. PMID: 33545391, PMCID: PMC8085597, DOI: 10.1016/j.molmet.2021.101178.Peer-Reviewed Original ResearchConceptsFatty liver diseaseLiver diseaseSmall molecule mitochondrial uncouplersTherapeutic potentialMitochondrial uncouplerNon-human primate studiesType 2 diabetesWide therapeutic indexSystemic toxicity concernsTreatment of MetabolicCell-specific effectsInsulin resistanceTherapeutic indexMetabolic diseasesNonalcoholic hepatosteatosisSustained increaseToxicity concernsPrimate studiesDiseaseTherapeutic developmentMitochondrial inefficiencyNutrient oxidationATP productionTreatmentTissue
1993
Comparative Effects of Monomethylsuccinate and Glucose on Insulin Secretion from Perifused Rat Islets
Zawalich W, Zawalich K, Cline G, Shulman G, Rasmussen H. Comparative Effects of Monomethylsuccinate and Glucose on Insulin Secretion from Perifused Rat Islets. Diabetes 1993, 42: 843-850. PMID: 8388341, DOI: 10.2337/diab.42.6.843.Peer-Reviewed Original ResearchConceptsPhosphoinositide hydrolysisInsulin secretionCalcium channel antagonist nitrendipineChannel antagonist nitrendipinePerifused rat isletsCalcium channel antagonistsSecond phase releaseGut hormone cholecystokininFirst-phase releaseInsulinotropic effectAntagonist nitrendipineSulfonylurea tolbutamideChannel antagonistsInsulin releaseHormone cholecystokininSubsequent stimulationGlucose-induced responseRat isletsSustained increaseStimulatory effectBiphasic patternMM glucoseMMSuccSecretionMonomethylsuccinate